2026 Scrip Asia 100
Latest Updates And Considerations In Asia Pacific
Japan
Japan stands at a crossroads where U.S. policy pressures, rising private equity interest, and landmark deals are testing its willingness to reform. The outcome could reshape the nation’s role in global pharma and investment.
Multiple Factors Behind Accelerating Private Equity Plays In Japan, APAC
By Ian Haydock and Lisa Takagi
With two major deals since just the beginning of the year in Japan, private equity groups appear to be ramping up their presence in the country's biopharma sector, amid ongoing activity across the wider APAC region.
Activist Investor Vs. Japan Pharma: ASKA Plans Poison Pill As Dalton Pushes For MBO
By Lisa Takagi
While ASKA plans to dilute the holding of largest investor Dalton by issuing new shares, the US investment firm continues to push a management buyout option to the mid-sized Japanese pharma company.